Carrie L. Moland Source Confirmed

Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.

High Impact

Researcher

National Center for Toxicological Research

faculty

28 h-index 47 pubs 3,326 cited

Is this your profile? Verify and claim your profile

Biography and Research Information

OverviewAI-generated summary

Carrie L. Moland investigates the mechanisms underlying cardiotoxicity induced by the chemotherapy drug doxorubicin. Her research has focused on identifying potential circulating biomarkers for early detection of this adverse effect, particularly focusing on microRNA-34a-5p as a preclinical indicator. Moland's work also explores the delayed-onset and subclinical manifestations of doxorubicin-induced cardiotoxicity in mouse models.

Further research by Moland examines sex-related differences in doxorubicin-induced cardiotoxicity, investigating the potential role of the apelin-APJ pathway in these differential responses. Her scholarship includes 47 publications with 3,326 citations and an h-index of 28, designating her as a highly cited researcher. She has collaborated with researchers Vikrant Vijay, James C. Fuscoe, and Bounleut Phanavanh at the National Center for Toxicological Research, as well as Kimo C. Stine at the University of Arkansas for Medical Sciences.

Metrics

  • h-index: 28
  • Publications: 47
  • Citations: 3,326

Selected Publications

  • Potential role of the apelin‐APJ pathway in sex‐related differential cardiotoxicity induced by doxorubicin in mice (2022) DOI
  • MicroRNA‐34a‐5p as a promising early circulating preclinical biomarker of doxorubicin‐induced chronic cardiotoxicity (2022) DOI
  • Doxorubicin‐induced delayed‐onset subclinical cardiotoxicity in mice (2021) DOI

Collaborators

Researchers in the database who share publications

Similar Researchers

Based on overlapping research topics